亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Tirofiban vs standard antiplatelet therapy in acute branch atheromatous disease-related stroke: a multicenter, randomized, open-label, blinded-endpoint, parallel-group, phase III clinical trial

替罗非班 医学 临床试验 临床终点 内科学 阿司匹林 相伴的 改良兰金量表 人口 冲程(发动机) 血小板聚集抑制剂 随机对照试验 外科 不利影响 临床研究阶段 人口研究 入射(几何) 置信区间 氯吡格雷 麻醉
作者
Shengde Li,Hai‐Zhou Hu,Dingding Zhang,Bin Liu,Mengfei Zhong,Lihua Wang,杨青松,Ping Zhang,Zhao Weili,FengLi Zhao,Yufeng Tang,Xiaoli Wang,Heng Li,Liwei Chen,Guofang Chen,Rui Wang,Aiqin Dong,Zhidong Zheng,Xiaona Wang,Qin Liu
出处
期刊:The Lancet Regional Health - Western Pacific [Elsevier BV]
卷期号:75: 101995-101995 被引量:1
标识
DOI:10.1016/j.lanwpc.2026.101995
摘要

Background: Tirofiban is sometimes used empirically for branch atheromatous disease (BAD)-related stroke, but its benefit in this population remains unclear. This study aimed to assess the efficacy and safety of intravenous tirofiban administered within 48 h of onset in patients with acute BAD-related stroke. Methods: This multicentre, randomized, open-label, blinded-endpoint clinical trial enrolled patients with BAD-related stroke within 48 h of onset from 25 hospitals in China between 9 November 2023 and 22 November 2025. Eligible patients were randomly assigned to the tirofiban group (intravenously, 0.4 μg/kg per minute for 30 min, followed by a 0.1 μg/kg per minute for 47.5 h) or standard antiplatelet therapy group (oral aspirin with or without clopidogrel) for 48 h. The primary endpoint was an excellent functional outcome, defined as a score of 0 or 1 on the modified Rankin Scale at 90 days. Safety outcomes included major bleeding within 90 days. This trial was registered on ClinicalTrials.gov (NCT06037889). Findings: Among 516 patients randomized, 513 were included in the primary analysis (258 with tirofiban and 255 with standard antiplatelet therapy). An excellent functional outcome was observed in 181 of 258 patients (70.2%) in the tirofiban group and 178 of 255 (69.8%) in the standard antiplatelet therapy group (risk ratio, 1.01 [95% CI, 0.90-1.13]; P = 0.93). Major bleeding occurred in 0 of 259 participants in the tirofiban-exposed safety population and 1 of 245 (0.4%) in the standard-antiplatelet-exposed safety population. Interpretation: Among patients with acute BAD-related stroke, intravenous tirofiban administered within 48 h of onset without concomitant oral antiplatelet therapy was not superior to standard antiplatelet therapy for achieving an excellent functional outcome at 90 days. These findings should not be extrapolated to substantially earlier treatment or to other tirofiban-based antiplatelet strategies. Funding: National High Level Hospital Clinical Research Funding, Capital's Funds for Health Improvement and Research, CAMS Innovation Fund for Medical Sciences (CIFMS), Noncommunicable Chronic Diseases-National Science and Technology Major Project, and China Shijiazhuang Pharmaceutical Company (CSPC) NBP Pharmaceurical Co., Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李斌发布了新的文献求助10
1秒前
ALKUT完成签到,获得积分10
1秒前
2秒前
3秒前
4秒前
5秒前
6秒前
7秒前
肖可声发布了新的文献求助10
9秒前
可乐发布了新的文献求助10
10秒前
10秒前
苗条的之桃完成签到,获得积分10
10秒前
儒雅傲人发布了新的文献求助10
12秒前
儒雅傲人发布了新的文献求助10
12秒前
充电宝的应助被可乐采纳,获得10
17秒前
YX给YX的求助进行了留言
18秒前
19秒前
完美的睿渊完成签到,获得积分10
20秒前
rongrongrong完成签到,获得积分10
22秒前
JamesPei的应助被Brightfuture采纳,获得10
24秒前
25秒前
26秒前
儒雅傲人完成签到,获得积分10
28秒前
打打的应助被虚幻的凌珍采纳,获得10
29秒前
真实的瑾瑜完成签到 ,获得积分10
31秒前
科研通AI6.3的应助被风趣含双采纳,获得10
32秒前
mohamed123发布了新的文献求助10
32秒前
33秒前
33秒前
啥子组蛋白完成签到,获得积分10
34秒前
KKIII发布了新的文献求助10
35秒前
Brightfuture发布了新的文献求助10
38秒前
39秒前
小蘑菇的应助被儒雅傲人采纳,获得10
40秒前
田様的应助被儒雅傲人采纳,获得10
40秒前
43秒前
沉默的涔完成签到 ,获得积分10
45秒前
Ava的应助被儒雅傲人采纳,获得10
46秒前
CipherSage的应助被儒雅傲人采纳,获得10
46秒前
慕青的应助被儒雅傲人采纳,获得10
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565479
关于积分的说明 21780029
捐赠科研通 7764837
什么是DOI,文献DOI怎么找? 3431499
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476579